AI-driven medication research and development (R&D) is breaking new ground and supplying more patients with faster and more effective treatment alternatives globally.
Yesterday, XtalPi revealed that they have begun a strategic partnership with CK Life Sciences, a part of the CK Hutchison Group. XtalPi and CK Life Sciences will combine their respective skills to create a revolutionary AI tumor vaccine R&D platform to increase tumor vaccine discovery and design capabilities and speed the development of new vaccine kinds. The collaboration’s purpose is to provide precise therapy to patients all across the world.
According to published data, there will be roughly 20 million newly diagnosed cancer patients globally in 2021, with China accounting for around 4.5 million cases. Many cancer types have negative results, with high morbidity and death, and there is a significant unmet clinical need. Tumor vaccines that target various tumor neoantigens, tumor-associated antigens (TAA), and tumor-specific antigens (TSA) in patients can be designed for use as immunotherapy, activating the patient’s own specific immune responses.
Currently, the US Food and Drug Administration has licensed just two therapeutic tumor vaccines, sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventative tumor vaccines against human papillomavirus infection and hepatitis B infection (FDA). Several more tumor vaccines have just entered clinical trials, and evidence of effectiveness is beginning to appear.
Mordor Intelligence estimates that the worldwide market for cancer vaccines was worth US$6.79 billion in 2021 and would rise at a compound yearly growth rate of 11.53% from 2022 to 2026. By 2026, the market is estimated to be worth around US$12 billion.
The design and preclinical development process for tumor vaccines are currently difficult and time-consuming, impeding the efficiency and success rate of tumor vaccine research and development.
This cooperation intends to establish an AI tumor vaccine R&D platform that uses sophisticated AI algorithms and high-precision molecular modeling to predict and design a variety of tumor vaccines that can stimulate particular immune responses to eliminate tumors. The tumor vaccines will be screened and validated using automated studies, and the platform is intended to develop preclinical tumor vaccine candidate molecules with robust immune activity by incorporating algorithmic input to optimize activity and efficacy.
Dr. Shuhao Wen, co-founder, and chairman of XtalPi, comments: “As a company headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi is committed to realizing the synergies between Shenzhen and Hong Kong by creating a new paradigm for innovation in the Greater Bay Area. Empowered by the latest technological advancements in automation, artificial intelligence is accelerating more innovative and diverse areas in drug research and development. Together with CK Life Sciences, we are committed to overcoming conventional limitations and discovering diverse applications for cutting-edge technologies. We believe the AI cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to progress vaccine research and development and fast-track key development milestones for cancer vaccines. We are confident that this collaboration will significantly facilitate the scientific research exchange in the Greater Bay Area.”
Dr. Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, comments: “The R&D of tumor vaccines is one of the key development directions of CK Life Sciences. The cooperation with XtalPi will apply XtalPi’s AI algorithm, molecular modeling, and automated experiments to speed up the R&D process, improve the success rate, and increase the efficacy of tumor vaccines.”
Source: Health economics.
